Stock Taper
SCREENER COMPARE ANY 2 STOCKS
PRQR
PROQR THERAPEUTICS N.V.
NASDAQ
$2.07
▼ DOWN 0.96% (-0.02)

KEY STATISTICS

Market Cap$217.99 M
52w High$3.10
52w Low$1.33
Dividend Yield—
Frequency—
P/E-4.50
Volume368.45K
Shares Out.105.31M

COMPANY

LEADERSHIP

Daniel Anton de Boer
CHIEF EXECUTIVE
Daniel Anton de Boer

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 18, 2014
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
166

PRICE TARGET

Target High$3.00
Target Low$3.00
Target Median$3.00
Target Consensus$3.00

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$3.84M
NOV
5
THU

PRICE

$2.07 ▼ DOWN 0.96% (−$0.02)
$2.07$2.08$2.09$2.109:31 AM10:36 AM11:40 AM12:45 PM1:50 PM2:54 PM3:59 PM2.07

About ProQR Therapeutics N.V.

https://www.proqr.com ↗

ProQR Therapeutics develops RNA-based therapies for genetic disorders, including sepofarsen and ultevursen in clinical trials, and owns an RNA editing platform, with collaborations and licenses with multiple research institutions and companies.

INDUSTRY

Biotechnology

A PRODUCT PROQR THERAPEUTICS N.V. IS KNOWN FOR

AX-0810
AX-0810

AX-0810, ProQR's lead Axiomer™ RNA therapy targeting the NTCP receptor, aims to treat cholestatic diseases, with clinical trial plans in 2025 and initial data expected by year's end.

COMPETITORS

COMPETITOR
ALNY COMPARE
ARWR COMPARE
CRSP COMPARE
EDIT COMPARE
IONS COMPARE

Revenue by Products

IconPRODUCTFY2021FY2022FY2023FY2024
Upfront payments$252K $56.25M ▲$6M ▼$15.58M ▲
Milestone payments— — — $5.1M
Premiums on share issue$168K $369K ▲— —
RD services$282K $273K ▼— —

ETFS HOLDING THIS STOCK

ETFS HOLDING
15
LISTED HERE
2
RANKED BY POSITION SIZE
D5BM.DE
0.00% · 55.8K
MSGR
1.54% · 21.7K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
30.81%
HOLDERS
89
TOP 12 OF 89 · RANKED BY POSITION SIZE
Adage Capital Partners Gp, L.L.C.
6.3M sh · $10.13M
Privium Fund Management B.V.
5.5M sh · $8.86M
Affinity Asset Advisors, LLC
3.6M sh · $7.67M
Abrdn Plc
3.3M sh · $5.37M
Morgan Stanley
2.9M sh · $6.18M
Sio Capital Management, LLC
2.2M sh · $4.37M
Kynam Capital Management, LP
1.6M sh · $3.51M
Dafna Capital Management LLC
1.6M sh · $2.54M
Siren, L.L.C.
1.6M sh · $3.31M
Ikarian Capital, LLC
1.5M sh · $2.42M
Arrowmark Colorado Holdings LLC
1.2M sh · $2.65M
Platinum Investment Management Ltd
1.2M sh · $2.5M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
de Boer Daniel Anton
Purchase · 200.0K shares
2026-07-31
★
DIRECTOR
Filius Bart
Purchase · 150.0K shares
2026-07-17
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
de Boer Daniel Anton
Purchase · 150.0K shares
2026-07-09
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
de Boer Daniel Anton
Purchase · 150.0K shares
2026-07-07

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
OUTPERFORM 1
3 GRADES IN THE LAST 12 MONTHS
Evercore ISI Group OUTPERFORM Chardan Capital BUY Jones Trading BUY

SECTORS PEERS

PEERPRICE
ACHV$8.49COMPARE
ALLO$1.98COMPARE
ZURA$6.19COMPARE
CAPR$9.50COMPARE
EDIT$3.16COMPARE
ARCT$15.97COMPARE
VNDA$5.41COMPARE
TRDA$7.13COMPARE